Media Update, page-460

Very positive article regards LumosThat's good for AT1.

Bright start for rapid tester Lumos, but Australia not its target

disallowed/business/entrepreneurship/bright-start-for-rapid-tester-lumos-but-australia-not-its-target-20210705-p586u6.html

I think the share price for At1 is being unfairly tarnished by the Australian market and perceptions of it. It's fine with me if it stays low for a while. Anything buys around IPO price should be justified as a decent investment shortly in 2022.

" Dr Sambursky said that on a global scale, however, rapid testing for coronavirus looked set to be a significant part of the diagnostics industry for the long term.."